Figure 5. Contribution of different anti-gp120 specificities for the cross-reactive neutralizing activity of AC053 plasma. (.

A) Log10 decrease in IC50 titers by elimination of anti-WT SF162 gp120 or competition of anti-D368R SF162 gp120 antibodies, as reported in [14], which demonstrates the CAAN is not susceptible to the anti-CD4BS cross-reactive NAb responses of AC053. (B) Log10 decrease in IC50 titers by elimination of anti-WT SF162 gp120 or anti-K160N SF162 antibodies, indicative of a glycan-specific cross-neutralizing response. Light blue: no effect or less than 0.5 Log10 decrease; Orange: decrease between 0.5 and 0.9 Log10; Red: over 0.9 Log10 decrease.